{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:03:55Z","timestamp":1787162635544,"version":"build-2736575974"},"reference-count":61,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1053\/j.seminhematol.2025.02.001","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T19:13:09Z","timestamp":1739387589000},"page":"31-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Extramedullary myeloma in the era of CAR T-cell and bispecific antibody therapies"],"prefix":"10.1053","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9353-7680","authenticated-orcid":false,"given":"Larysa","family":"Sanchez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shambavi","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2025.02.001_bib0001","unstructured":"SEER Cancer stat facts: myeloma. National Cancer Institute. Bethesda, MD."},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0002","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0003","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.2011.34.9290","article-title":"Soft tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach","volume":"29","author":"Blad\u00e9","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0004","first-page":"890","article-title":"Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the chronic malignancies working party of the EBMT","volume":"103","author":"Gagelmann","year":"2018","journal-title":"Haematologica"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.02.001_bib0005","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1080\/10428190802657751","article-title":"The impact of extramedullary disease at presentation in outcome of myeloma","volume":"50","author":"Wu","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0006","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.3109\/10428194.2012.740562","article-title":"Extramedullary multiple myeloma","volume":"54","author":"Weinstock","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0007","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.blre.2019.04.002","article-title":"Extramedullary disease in multiple myeloma - controversies and future directions","volume":"36","author":"Sevcikova","year":"2019","journal-title":"Blood Rev"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0008","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11899-020-00568-3","article-title":"Extramedullary disease in multiple myeloma","volume":"15","author":"Jagosky","year":"2020","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0009","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjh.17338","article-title":"Expert review of soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations","volume":"194","author":"Rosi\u00f1ol","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","article-title":"Extramedullary disease in multiple myeloma: a systematic literature review","volume":"12","author":"Blade","year":"2022","journal-title":"Blood Ca J"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0011","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3324\/haematol.2013.094409","article-title":"Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse","volume":"99","author":"Pour","year":"2014","journal-title":"Haematologica"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.02.001_bib0012","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4110\/in.2017.17.4.250","article-title":"Distinct clinical outcomes between paramedullary and extramedullary lesions in newly diagnosed multiple myeloma","volume":"17","author":"Batsukh","year":"2017","journal-title":"Immune Netw"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0013","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00277-014-2216-8","article-title":"Impact of extramedullary plasmacytomas on outcomes according to treatment approach in newly diagnosed symptomatic multiple myeloma","volume":"94","author":"Lee","year":"2015","journal-title":"Ann. Hematol."},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101465","article-title":"Advances in the treatment of extramedullary disease in multiple myeloma","volume":"22","author":"Li","year":"2022","journal-title":"Transl Oncol"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0015","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3324\/haematol.2012.065698","article-title":"Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents","volume":"97","author":"Usmani","year":"2012","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0016","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/annonc\/mdp329","article-title":"Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients","volume":"21","author":"Varettoni","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0017","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1600-0609.2008.01087.x","article-title":"Clinicopathological features of extramedullary recurrence\/relapse of multiple myeloma","volume":"81","author":"Cerny","year":"2008","journal-title":"Eur. J. Haematol."},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0018","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/leu.2011.29","article-title":"Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma","volume":"25","author":"Short","year":"2011","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0019","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3324\/haematol.2019.219295","article-title":"A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome","volume":"105","author":"Beksac","year":"2020","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0020","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/ajh.25579","article-title":"Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients","volume":"94","author":"Avivi","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0021","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3390\/cancers12041035","article-title":"Carfilzomib based treatment strategies in the management of relapsed\/refractory multiple myeloma with extramedullary disease","volume":"12","author":"Zhou","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0022","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s00277-014-2023-2","article-title":"The lymphoma-like polychemotherapy regimen \u201cDexa-BEAM\u201d in advanced and extramedullary multiple myeloma","volume":"93","author":"Rasche","year":"2014","journal-title":"Ann Hematol"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.02.001_bib0023","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/ajh.27023","article-title":"Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma","volume":"98","author":"Zanwar","year":"2023","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.02.001_bib0024","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41375-021-01343-w","article-title":"Limited efficacy of daratumumab in multiple myeloma with extramedullary disease","volume":"36","author":"Jelinek","year":"2022","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0025","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0026","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1073\/pnas.1819745116","article-title":"Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma","volume":"116","author":"Xu","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0027","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.720571","article-title":"Efficacy of humanized anti-BCMA CAR T cell therapy in relapsed\/refractory multiple myeloma patients with and without extramedullary disease","volume":"12","author":"Deng","year":"2021","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1053\/j.seminhematol.2025.02.001_bib0028","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0029","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0030","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti\u2013B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"JCO"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0031","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2020-134319","article-title":"Idecabtagene Vicleucel (ide-cel, bb2121) in relapsed and refractory multiple myeloma: analyses of high-risk subgroups in the KarMMa study","author":"Raje","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.02.001_bib0032","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2020-140243","article-title":"Chimeric antigen receptor T cell therapy in the relapsed or refractory multiple myeloma with extramedullary disease-a single institution observation in China","volume":"136","author":"Wang","year":"2020","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.02.001_bib0033","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1182\/blood-2022-170119","article-title":"Extramedullary relapse post CAR-T","volume":"140","author":"Richard","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0034","first-page":"1006","article-title":"Outcomes after CAR T cells in multiple Myeloma patients with extramedullary and paramedullary disease","author":"Pan","year":"2023","journal-title":"ASH"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0035","doi-asserted-by":"crossref","unstructured":"Zanwar S., Ho M., Kapoor P. Treatment patterns for extramedullary multiple myeloma and outcomes with CAR-T therapy and bispecific antibodies. J Clin Oncol 41 Number 16.","DOI":"10.1200\/JCO.2023.41.16_suppl.8022"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0036","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/hon.2958","article-title":"Efficacy and follow-up of humanized anti-BCMA CAR-T cell therapy in relapsed\/refractory multiple myeloma patients with extramedullary-extraosseous, extramedullary-bone related, and without extramedullary disease","volume":"40","author":"Li","year":"2022","journal-title":"Hematol Oncol"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.755866","article-title":"Anti-BCMA CAR-T cell therapy in relapsed\/refractory multiple myeloma patients with extramedullary disease: a single center analysis of two clinical trials","volume":"12","author":"Que","year":"2021","journal-title":"Front Immunol"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0038","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0039","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41408-024-01068-w","article-title":"Impact of extraosseous extramedullary disease on outcomes of patients with relapsed-refractory multiple myeloma receiving standard-of-care chimeric antigen receptor T-cell therapy","volume":"14","author":"Dima","year":"2024","journal-title":"Blood Ca J"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0040","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2022.282510","article-title":"Impact of high-risk disease on the efficacy of chimeric antigen receptor T-cell therapy for multiple myeloma: a meta-analysis of 723 patients","author":"Gagelmann","year":"2023","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0041","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13045-024-01555-4","article-title":"Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel","volume":"17","author":"Zanwar","year":"2024","journal-title":"J Hematol Oncol"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0042","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.1182\/blood-2023-173256","article-title":"Efficacy and safety of BCMA-specific CAR T cell-based therapy in relapsed\/refractory multiple myeloma patients with extramedullary disease","volume":"142","author":"Qi","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0043","unstructured":"CAR-T Cell therapy in RelApsed\/refractory myeloma with ExtrameduLlary disease - an in vivo imaging and Molecular monitoring study (CARAMEL): trial ID: NCT05666700, ClinicalTrials.gov."},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0044","first-page":"2002","article-title":"Saoirse Bodnar 3, MD et al. Inammatory marker levels, age, race and prior treatment burden independently predict delayed hematologic recovery after BCMA-directed CART","volume":"142","author":"Thibaud","year":"2023","journal-title":"Ther Multiple Myeloma Blood"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0045","doi-asserted-by":"crossref","unstructured":"Einsele H., Otero-Rodriguez P., Arnuff B., et al. Idecabtagene vicleucel (ide-cel) versus standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: karMMa-3 subgroup analysis in patients receiving bridging therapy. IMS 2023 poster presentation abstract # P-008.","DOI":"10.1016\/S2152-2650(23)01626-9"},{"issue":"23","key":"10.1053\/j.seminhematol.2025.02.001_bib0046","doi-asserted-by":"crossref","first-page":"6580","DOI":"10.1158\/1078-0432.CCR-21-0308","article-title":"The safety of bridging radiation with anti-BCMA CAR T-cell therapy for multiple myeloma","volume":"27","author":"Manjunath","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0047","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0048","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elrantamab in relapsed or refcractory myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0049","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for the treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0050","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0051","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.8003","article-title":"Talquetamab plus daratumumab in patients with relapsed\/refractory multiple myeloma: updated TRIMM-2 results","volume":"41","author":"Dholaria","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0052","series-title":"First results from the RedirecTT-1 study with teclistamab (TEC)\u202f+\u202ftalquetamab (TAL) simultaneously targeting BCMA and GPRC5D in patients (PTS) with relapsed\/refractory multiple myeloma (RRMM)","first-page":"8","author":"Mateos","year":"2023"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0053","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","article-title":"Real-world analysis of teclistamab in 123 RRMM patients from Germany","volume":"38","author":"Riedhammer","year":"2024","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0054","first-page":"e1","article-title":"Safety and efficacy of teclistamab in patients with relapsed\/refractory multiple myeloma: a real-world experience","volume":"30","author":"Dima","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0055","doi-asserted-by":"crossref","first-page":"S370","DOI":"10.1016\/j.jtct.2024.04.002","volume":"30","author":"Dima","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0056","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1182\/blood-2023-190019","article-title":"Efficacy of bispecific antibodies vs CAR-T in the treatment of extramedullary disease and high-risk cytogenetics in relapsed multiple myeloma: a systematic review and meta-analysis","volume":"142","author":"Vegivinti","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0057","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41408-024-01081-z","article-title":"Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma","volume":"14","author":"Rees","year":"2024","journal-title":"Blood Ca J"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0058","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1182\/blood-2019-127305","article-title":"The lymphoma tumor microenvironment influences toxicity after CD19 CAR T cell therapy","volume":"134","author":"Jain","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.02.001_bib0059","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-tern outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"15","key":"10.1053\/j.seminhematol.2025.02.001_bib0060","doi-asserted-by":"crossref","DOI":"10.1172\/JCI167629","article-title":"Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy","volume":"133","author":"Robinson","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminhematol.2025.02.001_bib0061","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1182\/blood.2024024590","article-title":"Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfcuntion in extramedullary myeloma","volume":"144","author":"John","year":"2024","journal-title":"Blood"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196325000010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196325000010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T11:25:53Z","timestamp":1744197953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196325000010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0037196325000010"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.02.001","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extramedullary myeloma in the era of CAR T-cell and bispecific antibody therapies","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}